Curis, Inc. (CRIS) financial statements (2020 and earlier)

Company profile

Business Address 4 MAGUIRE ROAD
LEXINGTON, MA 02421
State of Incorp. DE
Fiscal Year End December 31
SIC 2836 - Biological Products, Except Diagnostic Substances (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

12/31/2019
Q4
9/30/2019
Q3
6/30/2019
Q2
3/31/2019
Q1
12/31/2018
Q4
9/30/2018
Q3
6/30/2018
Q2
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments, including:21283543243140
Cash and cash equivalents15212743242630
Short-term investments57801510
Other undisclosed cash, cash equivalents, and short-term investments(0)(0)(0)00(0)(0)
Restricted cash and investments0000   
Receivables3322333
Other undisclosed current assets1211111
Total current assets:25333845283544
Noncurrent Assets
Operating lease, right-of-use asset001 
Property, plant and equipment0000000
Intangible assets, net (including goodwill)9999999
Goodwill9999999
Restricted cash and investments1   000
Other noncurrent assets0000000
Other undisclosed noncurrent assets   1   
Total noncurrent assets:10101010999
TOTAL ASSETS:35424855374453
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities6444668
Accounts payable4222334
Accrued liabilities2221333
Debt001 777
Other undisclosed current liabilities   1(0)  
Total current liabilities:7545131315
Noncurrent Liabilities
Long-term debt and lease obligation    293032
Long-term debt, excluding current maturities    293032
Liabilities, other than long-term debt    000
Other liabilities    000
Other undisclosed noncurrent liabilities62646465   
Total noncurrent liabilities:62646465293032
Total liabilities:69686969424346
Stockholders' equity
Stockholders' equity attributable to parent(34)(26)(20)(14)(4)17
Common stock0000000
Additional paid in capital983982981981980979978
Accumulated other comprehensive income (loss) 0    (0)
Accumulated deficit(1,017)(1,008)(1,002)(995)(985)(979)(972)
Total stockholders' equity:(34)(26)(20)(14)(4)17
TOTAL LIABILITIES AND EQUITY:35424855374453

Income statement (P&L) ($ in millions)

12/31/2019
Q4
9/30/2019
Q3
6/30/2019
Q2
3/31/2019
Q1
12/31/2018
Q4
9/30/2018
Q3
6/30/2018
Q2
Gross profit:3322332
Operating expenses(11)(8)(8)(7)(8)(9)(10)
Operating loss:(7)(5)(6)(6)(5)(6)(8)
Nonoperating expense(1)(1)(1)(4)(1)(1)(1)
Investment income, nonoperating00     
Other nonoperating income (expense)(0)0(1)(4)(1)(1)(1)
Interest and debt expense  (0)(3)(1)(1)(1)
Net loss:(9)(6)(7)(13)(7)(8)(10)
Other undisclosed net income attributable to parent  03111
Net loss available to common stockholders, diluted:(9)(6)(7)(10)(6)(7)(9)

Comprehensive Income ($ in millions)

12/31/2019
Q4
9/30/2019
Q3
6/30/2019
Q2
3/31/2019
Q1
12/31/2018
Q4
9/30/2018
Q3
6/30/2018
Q2
Net loss:(9)(6)(7)(13)(7)(8)(10)
Comprehensive loss:(9)(6)(7)(13)(7)(8)(10)
Other undisclosed comprehensive income (loss), net of tax, attributable to parent(0)003111
Comprehensive loss, net of tax, attributable to parent:(9)(6)(7)(10)(6)(7)(9)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: